Literature DB >> 2796852

Japanese experience of screening.

T Takeda1, Y Hatae, H Nakadate, M Nishi, J Hanai, Y Sato, N Takasugi.   

Abstract

In Sapporo City, the mass-screening for neuroblastoma concerning the urine of infants at about 6 months of age, started in 1981. After 1984, the quantitative determination of VMA, HVA in the urine was carried out using high performance liquid chromatography from the first step. About 104,000 babies have received the screening during the last 7 years, and 19 patients were found (incidence of detection 1:5,500). Except for one, who died of the duodenal perforation shortly after the surgery, all other patients are surviving free from disease. Among 10,000 neonates, we determined urinary concentration of VMA, HVA, and no positive cases were found. However, from this group, 2 patients we detected by the mass-screening at 6 months of age (1:5,000). After the start of mass-screening, the number of the patients with this tumor in much earlier stages and younger ages increased, clarifying that the main cause for improvement of the survival rates of neuroblastoma in Sapporo.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2796852     DOI: 10.1002/mpo.2950170504

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  3 in total

Review 1.  Screening for neuroblastoma.

Authors:  S N Huddart; J R Mann
Journal:  Arch Dis Child       Date:  1991-11       Impact factor: 3.791

2.  Mass-screening of neuroblastoma using urine from infants by high-performance liquid chromatographic method: results of first (6th month) and second (14th month) screening.

Authors:  T Takeda; M Shimada; M Nishi; J Hanai; Y Kikuchi
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

3.  Autoantibody signature differentiates Wilms tumor patients from neuroblastoma patients.

Authors:  Jana Schmitt; Andreas Keller; Nasenien Nourkami-Tutdibi; Sabrina Heisel; Nunja Habel; Petra Leidinger; Nicole Ludwig; Manfred Gessler; Norbert Graf; Frank Berthold; Hans-Peter Lenhof; Eckart Meese
Journal:  PLoS One       Date:  2011-12-16       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.